ELISA for the qualitative and highly sensitive detection of total (IgA, IgM and IgG) antibodies against Coronavirus SARS-CoV-2 in serum and plasma.

Benefits at a Glance:

  • Tests detect neutralizing antibodies directed against Receptor Binding
  • Domain (RBD) of spike protein of SARS-CoV-2 High specificity and sensitivity Results in 75 (Total Ab)  minutes
  • Ready-to-use reagents included
  • Tests are prepared for automation on open ELISA platforms
  • Developed, validated and manufactured in Marburg, Germany
  • EU: CE / IVD

Intended Use of DRG SARS-CoV-2 Antibody ELISAs

SARS-CoV-2 (RBD) Total Ab (EIA-6154); qualitative

  • Sensitive detection of prior virus infection (> 14 days after infection)
  • Support of diagnosis of COVID-19 disease, supplement of direct pathogen detection via RT-PCR or pulmonary CT-Scans
  • Support epidemiological studies for SARS-CoV-2
  • Monitor vaccination success

The DRG SARS-CoV-2 (RBD) total Ab ELISA is an enzyme immunoassay for the qualitative in vitro diagnostic measurement of IgG/IgM/IgA antibodies to SARS-CoV-2 in serum and plasma (EDTA, Li-heparin or citrate).

This specific ELISA is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. It can support the diagnosis of COVID-19 disease and supplement direct pathogen detection via RT-PCR or pulmonary CT-Scans. In addition, serology can help to gather epidemiological information on the disease prevalence.